New findings published in Nature Chemical Biology show promise for finding new solutions to treat lung cancer and other deadly diseases. Kentucky continues to lead the nation in incidence and death rates from lung cancer, and the University of Kentucky is committed to reducing these numbers.
According to the National Cancer Institute, cancer is among the leading causes of death worldwide. And of those diagnosed in the United States, lung cancer accounts for 25 percent of cancer deaths. The numbers are sobering: one out of every two patients diagnosed with lung cancer won’t survive past 12 months.
In an effort to combat this problem, a collaboration between scientists from University of Kentucky College of Pharmacy, Memorial Sloan Kettering Cancer Center, and St. Jude Children’s Research Hospital brings researchers one step closer to a solution.
A compound developed by Dean Kip Guy’s lab of UK College of Pharmacy, with research that began at St. Jude Children’s Research Hospital, now provides us with a way to block cancer-causing proteins on a cellular level.
The groundwork began more than 10 years ago when Dr. Bhuvanesh Singh, a physician-scientist at Memorial Sloan Kettering Cancer Center, identified that an increase of a protein called DCN1 led to more malignant lung cancers and shorter life spans for his patients. Of the patients he studied, those with high levels of DCN1 succumbed to the disease more quickly than those with normal levels.
Frustrated by their findings, Singh’s team set out to study the specifics of DCN1. While DCN1 is a normally occurring protein, his team found that too much of it leads directly to cancer formation. Simply put, a malignant tumor was formed when the amount of DCN1 in a cell was increased. Thus, patients with more DCN1 got sick more quickly and died faster than their counterparts.
Efforts in Brenda Schulman’s lab at St. Jude, led by biochemist Daniel Scott, established how DCN1 interacts with other proteins and controls cellular processes. Their key discovery used X-ray crystallography to show that a small modification of the partner protein to DCN1, known as UBE2M was required for DCN1 to work. This modification, N-terminal acetylation (while common) had not previously been shown to be critical to controlling activity of this specific protein. Recognizing the potential for targeting this modification, Schulman reached out to form a collaboration between the three laboratories.
Their goal: to develop a way to stop DCN1 from killing patients.
Understanding the behavior and function of DCN1 was far more ambitious than running simple tests. It was a significant step forward in understanding how proteins within a cell work.
Building upon the science from Schulman’s team, Jared Hammill from Guy’s lab and Danny Scott from Schulman’s lab worked to stop the interactions of DCN1 all together. If DCN1’s activity depended on this interaction, then it stood to reason they could create a compound to intervene and stop the interaction from happening.
Guy describes the interaction as a “lock and key model.” Scientists have a blank key—which is UBE2M—and a lock, which is DCN1. The key wants to fit into the lock so it’s modified until it fits. This modification process is N-terminal acetylation.
“What’s the significance?” Guy said. “Well, we’re the first people to show that protein interaction controlled by N-terminal acetylation can be blocked. We’re essentially jamming the lock with a compound so the key won’t fit.”
The items jamming that lock are a series of small molecules created in the lab. When the molecules were tested directly in cancer cells, they worked. They effectively blocked DCN1 from binding to UB2EM. After decades of collaborative research, there was finally a barrier between lock and key.
The impact of these findings for healthcare and lung cancer patients specifically could be profound.
“We are excited about the implications of this research, which offer us a meaningful solution for addressing diseases like cancer, neurodegenerative disorders, and infection,” Schulman said. “It’s exciting to collaborate with so many complementary groups of expertise and to watch how Dr. Scott and Dr. Hammill led the team. This research opens many new doors for us.”
The collaboration between these three labs could mean relief to many of those suffering from a variety of diseases.
“To have spent decades on this research and have such promising results is truly exhilarating,” Singh said. “At the end of the day, what matters most is improving health outcomes for our patients. This work represents a very important step towards developing a new approach to treat the most difficult of cancers and hopefully increase cure rates.”
Learn more: Blocking Cancer—Scientists Find New Way to Combat Disease
The Latest on: Block cancer
[google_news title=”” keyword=”block cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Triggering cancer cells to become normal cells – how stem cell therapies can provide new ways to stop tumors from spreading or growing backon June 4, 2023 at 4:02 pm
Stem cells are unspecialized cells, meaning they can eventually become any one of the various types of cells that make up different parts of the body. They can replenish cells in the skin, bone, blood ...
- SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphomaon June 4, 2023 at 11:10 am
A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy ...
- New combination therapy cuts risk of breast cancer returning by 25 per centon June 4, 2023 at 6:08 am
New York:Adding a novel drug to hormone therapy can help block the return of the most common form of breast cancer by 25 per cent, according to a study. Researchers found that patients with early ...
- Home for Healing celebrating 20 years with a weekend block partyon June 2, 2023 at 2:26 pm
Home for Healing celebrated their 20th anniversary on Saturday with the "The 20 Years on the Block Party."The Block Party was a free community event open to the ...
- OHSU's Knight Cancer Institute snares $1M-plus to study artificial tissueson June 2, 2023 at 11:03 am
The process, called biofabrication, is at the center of the newly formed Knight Cancer Precision Biofabrication Hub. The M.J. Murdock Charitable Trust contributed half the funding ...
- How to Reduce Your Risk of Skin Cancer, According to Dermatologistson June 2, 2023 at 8:14 am
When it comes to preventing skin cancer, I like to think we all know the sun safety basics. You apply your sunscreen (SPF 30 and up!) day in and day out, remember to reapply, and seek shade. But given ...
- New approach improves cancer treatment and minimizes side effectson June 2, 2023 at 2:20 am
Scientists have discovered a new approach to improve the efficacy of immune checkpoint blockade while minimizing the associated side effects.
- Meet The Pepperonis, A Chosen Family That’s Overcome Everything From Cancer To Pet Parade Upsetson June 1, 2023 at 7:00 am
Four Chicago transplants have formed a deep bond known as chosen family, a term for people who choose to embrace, support and love each other like relatives, regardless of blood or marriage.
- Tech Better Predicts Response To Leading Cancer Immunotherapyon June 1, 2023 at 2:05 am
Israeli researchers have developed a method of more accurately predicting the response of cancer patients to a leading course of immunotherapy ...
- Scientists identify how some angiogenic drugs used to treat cancer and heart disease cause vascular diseaseon May 31, 2023 at 5:59 am
Research by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has demonstrated that the on-target molecular and cellular effects of medicines used to modulate the formation ...
via Google News and Bing News